PFIZER疫苗加强剂疫苗有效率高达95.6%，同时安全度更高

CrisisInvesting

辉瑞药厂积极向各国政府申请，紧急批准使用疫苗加强剂。药厂最新发表的研究指出，完成接种后近1年打加强剂为最理想时间，有效率将超过95%，更能防范现时肆虐全球的Delta变种病毒。

辉瑞周四（21日）发表未经同行评审的研究为1万名16岁以上﹑接受早期疫苗试验的民众，在完成接种后11个月打加强剂。结果显示，疫苗有效率高达95.6%，同时安全度更高，而且能够对抗Delta变种（首先在印度发现）。


研究分别为有关人士接种加强剂或安慰剂，加强剂组别中，只有5宗确诊，反之安慰剂组别多达109人确诊。实验参与者年龄届乎16至55岁达55.5%，65岁或以上占23.3%，年龄中位数为53岁。

美国投行Jefferies分析师Michael Yee认为，实验数据证明加强剂有助防范有症状感染，以及提供长期保护。匹兹堡大学医学院教授盖拉特（Walid Gellad）指出，加强剂似乎亦有助防范无症状感染，但未知是否所有年龄层受惠。

CrisisInvesting

after 11 months, one should get 'booster shot'

tcm328pan

CrisisInvesting

看来十六岁以上的都要打第三针了。

CrisisInvesting

Among the big pharma companies that have reported so far, Bristol-Myers, Biogen, Gilead Sciences, Merck and Glaxo beat on both earnings and sales. J&J and BioMarin beat earnings estimates but missed the same for revenues. Lilly missed earnings estimates while outpacing estimates for revenues.

Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.

Per the Earnings Trends report, as of Oct 27, 25.5% of the companies in the Medical sector, constituting nearly 47.6% of the sector’s market capitalization, have reported earnings. While 78.6% beat earnings estimates, 85.7% beat the same for sales. Earnings increased 19.6% year over year on 12.1% higher revenues. Overall, third-quarter earnings for the Medical sector are expected to rise 21.8% on a 10.5% sales increase.

Zeroing in on the Winners
Here we have highlighted four drug/biotech companies, which are expected to deliver an earnings surprise in their upcoming quarterly results.

Earnings ESP is our proprietary methodology for determining the stocks that have the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.

According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be done with the help of the Zacks Stock Screener.

Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

4 Biotech Stocks That Match the Criteria
Pfizer Inc.’s PFE COVID-19 vaccine, Comirnaty, is likely to have been a key contributor to the company’s top line during the third quarter. Moreover, Pfizer’s key brands and new drugs are also likely to have aided sales. However, sales of several legacy drugs are likely to have been hurt by continued generic competition. (Read more: Will Pfizer Keep the Earnings Streak Alive in Q3?)

The combination of Pfizer’s Earnings ESP of +2.25% and a Zacks Rank #3 raises the possibility of an earnings surprise in the to-be-reported quarter.

The company is scheduled to release earnings for the third quarter of 2021 on Nov 2.

Pfizer Inc. Price and EPS Surprise
Pfizer Inc. Price and EPS Surprise
Pfizer Inc. Price and EPS Surprise
Pfizer Inc. price-eps-surprise | Pfizer Inc. Quote

Vertex Pharmaceuticals’ VRTX revenues are likely to have been driven by the rapid uptake of the company’s newest cystic fibrosis medicine, Trikafta/Kaftrio. (Read more: Vertex to Report Q3 Earnings: What's in the Cards?)

The company has an Earnings ESP of +10.62% and a Zacks Rank #2.

The company is scheduled to release earnings for the third quarter of 2021 on Nov 2.

Vertex Pharmaceuticals Incorporated Price and EPS Surprise
Vertex Pharmaceuticals Incorporated Price and EPS Surprise
Vertex Pharmaceuticals Incorporated Price and EPS Surprise
Vertex Pharmaceuticals Incorporated price-eps-surprise | Vertex Pharmaceuticals Incorporated Quote

Regeneron Pharmaceuticals, Inc.’s REGN top line is likely to have been driven by strong demand for Eylea and Dupixent during the third quarter. The antibody cocktail REGEN-COV for COVID-19 patients is likely to have brought additional revenues.

The company has an Earnings ESP of +8.78% and a Zacks Rank #1.

The company is scheduled to release earnings for the third quarter of 2021 on Nov 4.

Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Regeneron Pharmaceuticals, Inc. Price and EPS Surprise
Regeneron Pharmaceuticals, Inc. price-eps-surprise | Regeneron Pharmaceuticals, Inc. Quote

Zoetis Inc.’s ZTS revenues are likely to have been driven by the continued momentum of solid growth of key dermatology products during the third quarter. However, generic competition for some products is likely to hurt the top line.

The company has an Earnings ESP of +5.46% and a Zacks Rank of #3.

The company is scheduled to release earnings for the third quarter of 2021 on Nov 4.

Zoetis Inc. Price and EPS Surprise
Zoetis Inc. Price and EPS Surprise
Zoetis Inc. Price and EPS Surprise
Zoetis Inc. price-eps-surprise | Zoetis Inc. Quote

CrisisInvesting

Carl O'Donnell
Wed, November 3, 2021, 6:18 AM
In this article:

PFE
-0.42%

(Updates with shots being administered)

By Carl O'Donnell

Nov 3 (Reuters) - The United States on Wednesday started vaccinating children aged 5 to 11 against COVID-19, with roughly 28 million school-age kids now eligible for the shots that provide protection against the illness.

On Tuesday, the U.S. Centers for Disease Control and Prevention recommended the Pfizer Inc/BioNTech SE shot for broad use in that age group after a panel of outside advisers voted in favor of it.

While about 58% of Americans are fully vaccinated against COVID-19, children under 12 have not yet been eligible for shots. The Delta variant of the virus has led to thousands of children being hospitalized and they make up 25% of U.S. cases.

The vaccine, shown to be more than 90% effective at preventing symptomatic infection in children, offers an avenue for fewer quarantines or school closures and more freedoms.

"I think it's going to make the issue of schools much easier, much safer," White House chief medical adviser Dr. Anthony Fauci said in an interview with CNN on Wednesday.

The U.S. government is sending 15 million COVID-19 vaccines for children to distribution centers around the country, and while some vaccinations will be given as soon as Wednesday, shots will be more widely available starting the week of Nov. 8.

The shots will be available at pediatrician's offices, children's hospitals and pharmacies. The big national pharmacy chains, Walgreens Boots Alliance and CVS Health, will have them starting this weekend.

The federal government has purchased 50 million doses of Pfizer's vaccine to be deployed, U.S. officials said this week.

Pfizer's shot for younger children contains a lower 10-microgram dose of vaccine than the 30 micrograms given to those aged 12 and older.

The U.S. Food and Drug Administration authorized the Pfizer/ BioNTech vaccine for children aged 5 to 11 years on Friday. So far, only Pfizer's shot has been authorized for use in the United States for those under the age of 12. A few other countries, including China, are already vaccinating children